Press Releases
November 9, 2007
Xanodyne Pharmaceuticals, Inc. Files Registration Statement for Proposed Initial Public Offering
Newport, Kentucky, November 9, 2007 – Xanodyne Pharmaceuticals, Inc. announced
today that it has filed a registration statement with the U.S. Securities and Exchange
Commission relating to the proposed initial public offering of its common stock. The
number of shares to be offered and the price range for the proposed offering have not
yet been determined. All of the shares in the proposed offering will be sold by
Xanodyne.
Morgan Stanley & Co. Incorporated is acting as sole bookrunning manager for the
offering. Deutsche Bank Securities Inc. is co-lead manager, and RBC Capital Markets
and Natixis Bleichroeder Inc. are co-managers.
Xanodyne is an integrated specialty pharmaceutical company with both development
and commercial capabilities focused on women’s healthcare and pain management.
Xanodyne markets a portfolio of revenue generating products and is advancing a late
stage pipeline of product candidates targeted at significant potential markets in its focus
areas.
A registration statement relating to these securities has been filed with the Securities
and Exchange Commission but has not yet become effective. These securities may not
be sold nor may offers to buy be accepted prior to the time that the registration
statement becomes effective.
The offering will be made only by means of a prospectus. When available, copies of
the preliminary prospectus relating to this offering may be obtained by contacting
Morgan Stanley & Co. Incorporated, 180 Varick Street, New York, New York 10014,
Attention: Prospectus Department, or by email at prospectus@morganstanley.com.
Contact:
Stephen A. Stamp
Chief Financial Officer
Xanodyne Pharmaceuticals, Inc.
(859) 371-6383